Clinical Trial: An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency
Study Status: No longer available
Recruit Status: No longer available
Study Type: Expanded Access
Official Title: AN EXPANDED ACCESS PROTOCOL FOR SEBELIPASE ALFA FOR PATIENTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY
Brief Summary:
This is an open-label, multicenter expanded access protocol to allow patients with a confirmed diagnosis of Lysosomal Acid Lipase (LAL) Deficiency in the United States (US), access to sebelipase alfa (recombinant lysosomal acid lipase [rhLAL]) until commercial product is available.
Patients enrolled in the expanded access protocol will receive 1 mg/kg intravenous infusions of sebelipase alfa every other week.
Detailed Summary:
Sponsor: Alexion Pharmaceuticals
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Alexion Pharmaceuticals
Dates:
Date Received: February 25, 2015
Date Started:
Date Completion:
Last Updated: June 6, 2016
Last Verified: November 2015